YMTX vs. INDP, LUMO, SNSE, IBIO, PPBT, SYBX, VBIV, TCRT, KALA, and AYTU
Should you be buying Yumanity Therapeutics stock or one of its competitors? The main competitors of Yumanity Therapeutics include Indaptus Therapeutics (INDP), Lumos Pharma (LUMO), Sensei Biotherapeutics (SNSE), iBio (IBIO), Purple Biotech (PPBT), Synlogic (SYBX), VBI Vaccines (VBIV), Alaunos Therapeutics (TCRT), KALA BIO (KALA), and Aytu BioPharma (AYTU). These companies are all part of the "pharmaceutical preparations" industry.
Indaptus Therapeutics (NASDAQ:INDP) and Yumanity Therapeutics (NASDAQ:YMTX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, media sentiment, community ranking, profitability, institutional ownership, earnings and valuation.
Indaptus Therapeutics has a beta of 1.28, indicating that its stock price is 28% more volatile than the S&P 500. Comparatively, Yumanity Therapeutics has a beta of 0.32, indicating that its stock price is 68% less volatile than the S&P 500.
Indaptus Therapeutics has higher earnings, but lower revenue than Yumanity Therapeutics. Indaptus Therapeutics is trading at a lower price-to-earnings ratio than Yumanity Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Indaptus Therapeutics had 4 more articles in the media than Yumanity Therapeutics. MarketBeat recorded 4 mentions for Indaptus Therapeutics and 0 mentions for Yumanity Therapeutics. Yumanity Therapeutics' average media sentiment score of 1.79 beat Indaptus Therapeutics' score of 0.00 indicating that Indaptus Therapeutics is being referred to more favorably in the media.
Yumanity Therapeutics received 4 more outperform votes than Indaptus Therapeutics when rated by MarketBeat users. However, 83.33% of users gave Indaptus Therapeutics an outperform vote while only 70.00% of users gave Yumanity Therapeutics an outperform vote.
7.1% of Indaptus Therapeutics shares are held by institutional investors. Comparatively, 25.1% of Yumanity Therapeutics shares are held by institutional investors. 29.5% of Indaptus Therapeutics shares are held by insiders. Comparatively, 12.5% of Yumanity Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Indaptus Therapeutics has a net margin of 0.00% compared to Indaptus Therapeutics' net margin of -660.61%. Yumanity Therapeutics' return on equity of -108.14% beat Indaptus Therapeutics' return on equity.
Indaptus Therapeutics currently has a consensus price target of $12.00, suggesting a potential upside of 402.09%. Given Yumanity Therapeutics' higher probable upside, research analysts clearly believe Indaptus Therapeutics is more favorable than Yumanity Therapeutics.
Summary
Indaptus Therapeutics beats Yumanity Therapeutics on 12 of the 16 factors compared between the two stocks.
Get Yumanity Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for YMTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding YMTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Yumanity Therapeutics Competitors List
Related Companies and Tools
